Vertex Pharma (VRTX) Announces Health Canada Approval of PrORKAMBI as Underlying Cause of CF Treatment
Tweet Send to a Friend
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that Health Canada has approved PrORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
